Wyeth Receives Positive Opinion From European Regulators For Its 13-valent Pneumococcal Candidate Va

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
26th September 2009, 05:21am - Views: 679






Community Health Wyeth Pharmaceuticals 2 image










MEDIA RELEASE PR36299


Wyeth Receives Positive Opinion from European Regulators for its 13-valent Pneumococcal Candidate

Vaccine for Infants and Young Children


COLLEGEVILLE, Pa., Sept. 26 /PRNewswire-AsiaNet/ --


    Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines

Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the

company's pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine

[13-valent Adsorbed]). The CHMP recommends approval of Prevenar 13 for active immunization of children aged 6

weeks to 5 years for the prevention of invasive pneumococcal disease, as well as pneumonia and otitis media

(middle ear infection) caused by 13 pneumococcal serotypes. The CHMP's opinion for Prevenar 13 will now be

forwarded to the European Commission and a final decision is expected in the coming months.


    "The CHMP's positive opinion brings us one step closer to providing infants and young children in Europe with

the broadest serotype coverage of any pneumococcal conjugate vaccine," says Emilio Emini, Ph.D., Executive Vice

President, Vaccine Research and Development, Wyeth Pharmaceuticals. "Prevenar, our currently available

vaccine, has both proven clinical efficacy and documented effectiveness, which has resulted in a significant public

health benefit. Prevenar 13 builds on the scientific foundation of Prevenar and, if approved, will provide coverage

for the 13 most prevalent pneumococcal-disease causing serotypes, including serotype 19A, which has emerged

as a serious public health threat in Europe and around the world."


    Prevenar 13 is designed to provide the broadest serotype coverage of any pneumococcal conjugate vaccine.

The vaccine contains the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) included in Prevenar (Pneumococcal

Saccharide Conjugated Vaccine, Adsorbed) -- the global standard in pneumococcal disease prevention in infants

and young children -- plus six additional serotypes (1, 3, 5, 6A, 7F and 19A) responsible for the greatest remaining

burden of invasive disease. Both Prevenar and Prevenar 13 use CRM197 -- an immunological carrier protein with a

20-year history of use in pediatric vaccines. Available in Europe since 2001, Prevenar is currently available in 97

countries and more than 265 million doses have been distributed worldwide.


    To date, the company has submitted pediatric regulatory applications for Prevenar 13 in more than 50 countries

spanning six continents. Prevenar 13 has been approved in two countries, with Chile being the first in July 2009.

Prevenar 13 is also being studied in global Phase 3 clinical trials in

adults, with regulatory submissions expected in 2010.


    Important Safety Information for Prevenar 13

    In clinical studies, the most commonly reported adverse reactions were injection site reactions, fever, irritability,

decreased appetite, and increased and/or decreased sleep.


    Risks are associated with all vaccines, including Prevenar 13. Hypersensitivity to any component, including

diphtheria toxoid, is a contraindication to its use.


    As with other vaccines, the administration of Prevenar 13 should be postponed in subjects suffering from acute,

febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of

vaccination.


    The use of Prevenar 13 should be determined on the bases of official recommendations, taking into

consideration the impact of invasive disease in different age groups as well as the variability of serotype

epidemiology in different geographic areas. Prevenar 13 does not provide 100% protection against vaccine

serotypes or protect against nonvaccine serotypes.


    Important Safety Information for Prevenar

    In clinical studies (n=18,168), the most frequently reported adverse events included injection site reactions, fever

(greater than or equal to 38 degrees C/100.4 degrees F), irritability, drowsiness, restless sleep, decreased appetite,

vomiting, diarrhea, and rash.


    Risks are associated with all vaccines, including Prevenar. Hypersensitivity to any vaccine component, including

diphtheria toxoid, is a contraindication to its use. Prevenar does not provide 100% protection against vaccine

serotypes or protect against non-vaccine serotypes. The decision to administer Prevenar should be based on its

efficacy in preventing invasive pneumococcal disease.


    The frequency of pneumococcal serotypes and serogroups can vary from country to country, which could

influence the effectiveness of the vaccine in any given country.


    Pneumococcal Disease

    According to the World Health Organization (WHO), pneumococcal disease is the leading cause of vaccine-

preventable death worldwide in children younger than 5 years and is estimated to cause up to 1 million deaths

worldwide in children each year.


    Pneumococcal disease is complex and describes a group of illnesses, all caused by the bacterium

Streptococcus pneumoniae. Pneumococcal disease affects both children and adults, and includes invasive

infections such as bacteremia/sepsis and meningitis, as well as pneumonia and acute otitis media.


    Wyeth Pharmaceuticals

    Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care,

infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, haemophilia,

oncology, vaccines and nutritional products.


    Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a

leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology

products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The

Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal

Health.


    The statements in this press release that are not historical facts are forward-looking statements that are subject

to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by

such statements. In particular, clinical trial data are subject to differing interpretations, and the views of regulatory

agencies, medical and scientific experts and others may differ from ours. There can be no assurance that the

European Commission will grant final approval to Prevenar 13 or that Prevenar 13 will be commercially successful

or receive regulatory approval in other markets such as the United States. Other risks and uncertainties that could

cause actual results to differ materially from those expressed or implied by forward-looking statements include,

among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the

proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business

included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities

or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the

inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory

approval and commercialisation of our products and pipeline products; government cost-containment initiatives;

restrictions on third-party payments for our products; substantial competition in our industry, including from branded

and generic products; emerging data on our products and pipeline products; the importance of strong performance

from our principal products and our anticipated new product introductions; the highly regulated nature of our

business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of

government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties

associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with

our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and

volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying

patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global

operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic

reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly

reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk

Factors" in our Annual Report on Form 10-K for the year ended 31 December, 2008, which was filed with the

Securities and Exchange Commission on 27 February, 2009. The forward-looking statements in this press release

are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements,

whether as a result of new information, future developments or otherwise.


    *Trademark



SOURCE: Wyeth Pharmaceuticals


Community Health Wyeth Pharmaceuticals 3 image

    CONTACT: Media, 

                       Lili Gordon, 

                       +1-484-865-6671, 


                       or Douglas Petkus,

                       +1-973-660-5218, 


                       or Investors, 

                       Justin Victoria,  

                       +1-973-660-5340, 


                       all of Wyeth

    (WYE)

  








news articles logo NEWS ARTICLES
Contact News Articles |Remove this article